登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002550 证券简称：千红制药 公告编号：2025-035 常州千红生化制药股份有限公司 2025年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议的情形。 一、会议召开情况 （一）召开时间： 1、现场会议召开时间：2025年11月14日（周五）下午14:30 2、网络投票时间：2025年11月14日 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025年11月14日9:15-9:25，9:30-11:30， 13:00-15:00。 通过深圳证券交易所互联网投票系统投票的具体时间为：2025年11月14日9:15至15:00的任意时间。 本次股东大会采用现场表决与网络投票相结合的表决方式对以下议案进行了表决： （一）审议通过了《关于修订〈公司章程〉的议案》 表决结果： （二）召开地点：公司云河路厂区行政楼二楼会议室（江苏省常州市新北区云河路518号） （三）召开 ...

Core Viewpoint - Qianhong Pharmaceutical announced the election of Mr. Liu Jun as the employee representative director of the sixth board of directors [2] Group 1 - The company has made a formal announcement regarding the election of a new board member [2] - Mr. Liu Jun has been unanimously elected by the board [2]

Core Viewpoint - The company announced the resignation of non-independent director and vice president Mr. Hai Tao, which is part of a governance structure adjustment [1] Group 1 - Mr. Hai Tao submitted a written resignation report to the board of directors, effective immediately upon submission [1] - Following his resignation from the non-independent director position, Mr. Hai Tao will continue to serve as the vice president of the company [1] - As of the announcement date, Mr. Hai Tao does not hold any shares in the company and has no outstanding share lock-up commitments [1]

证券代码：002550 证券简称：千红制药 公告编号：2025-036 常州千红生化制药股份有限公司 关于公司非独立董事辞职暨选举职工代表董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事辞职情况 常州千红生化制药股份有限公司（以下简称"本公司"或"公司"）董事会 近日收到非独立董事兼副总经理海涛先生的书面辞职报告。基于公司治理结构的 调整，海涛先生申请辞去公司非独立董事的职务。辞去上述职务后，海涛先生仍 继续担任公司副总经理的职务。 海涛先生的辞职不会导致公司董事会成员人数低于《中华人民共和国公司法》 （以下简称"《公司法》"）、《深圳证券交易所上市公司自律监管指引第 1 号—— 主板上市公司规范运作》（2025 年修订）、《公司章程》等有关规定的最低人数， 不会影响董事会正常运行和公司的经营管理，其辞职报告自提交公司董事会之日 起生效。 特此公告！ 常州千红生化制药股份有限公司 董 事 会 截至本公告披露日，海涛先生未持有公司股份，不存在应当履行而未履行的 股份锁定承诺事项。 公司及董事会对海涛先生在任职期间为公司治理及发展所做出的贡献表 ...

常州千红生化制药股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 证券代码：002550 证券简称：千红制药 公告编号：2025-035 1、本次股东大会未出现否决议案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议的情形。 一、会议召开情况 （一）召开时间： 1、现场会议召开时间：2025 年 11 月 14 日（周五）下午 14:30 2、网络投票时间：2025 年 11 月 14 日 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 11 月 14 日 9:15-9:25，9:30-11:30，13:00-15:00。 通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 11 月 14 日 9:15 至 15:00 的任意时间。 （二）召开地点：公司云河路厂区行政楼二楼会议室（江苏省常州市新北区 云河路 518 号） （三）召开方式：现场表决与网络投票相结合 （四）召集人：公司董事会 （五）主持人：公司董事长王耀方先生 （六）本次股东大会的召集、召开程 ...

南京市鼓楼区集庆门大街 270 号苏宁环球国际中心 43 层 电话：025-85803866 传真：025-85803680 邮编：210003 北京国枫（南京）律师事务所 关于常州千红生化制药股份有限公司 2025 年第一次临时股东大会的 法律意见书 国枫律股字[2025]H0047 号 致：常州千红生化制药股份有限公司（贵公司） 北京国枫（南京）律师事务所（以下简称"本所"）接受贵公司的委托，指派律师 出席并见证贵公司 2025 年第一次临时股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证 券法律业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简 称"《证券法律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《常 州千红生化制药股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会 议的召集与召开程序、召集人资格、出席会议人员资格、会议表决程序及表决结果等 ...

Market Overview - The precision medicine sector experienced a slight decline of 0.01% on November 12, with Guomai Technology leading the drop [1] - The Shanghai Composite Index closed at 4000.14, down 0.07%, while the Shenzhen Component Index closed at 13240.62, down 0.36% [1] Stock Performance - Zhongyuan Xiehe saw a significant increase of 10.00%, closing at 28.61 with a trading volume of 311,400 shares and a transaction value of 857 million [1] - Yangpu Medical and Beilu Pharmaceutical also reported gains of 4.13% and 2.96%, respectively [1] - Guomai Technology, on the other hand, declined by 3.17%, closing at 11.62 [2] Capital Flow - The precision medicine sector saw a net inflow of 311 million from institutional investors, while retail investors experienced a net outflow of 318 million [2] - Major stocks like Zhongyuan Xiehe and Yaoming Kangde attracted significant institutional investment, with net inflows of 1.941 billion and 76.27 million, respectively [3] Individual Stock Highlights - Zhongyuan Xiehe had a net institutional inflow of 1.941 billion, accounting for 22.65% of its trading volume, while retail investors withdrew 932 million [3] - Yaoming Kangde also saw a net institutional inflow of 76.27 million, with retail investors withdrawing 430 million [3] - Other notable stocks with positive institutional inflows include Beilu Pharmaceutical and Yangpu Medical, with net inflows of 33.03 million and 26.56 million, respectively [3]

北京国枫律师事务所 北京国枫律师事务所 关于常州千红生化制药股份有限公司 实施 2025 年员工持股计划的 法律意见书 国枫律证字[2025]AN197-1 号 GRANDWAY Grandway Law Offices 北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 邮编: 100005 电话（Tel）: 010-88004488/66090088 传真（Fax）: 010-66090016 释 义 本法律意见书中,除非文义另有所指,下列词语或简称具有如下含义: | 千红制药、公司 | 指 | 常州千红生化制药股份有限公司 | | --- | --- | --- | | 本员工持股计划 | 損 | 千红制药 2025年员工持股计划 | | 《员工持股计划(草案)》 | 損 | 《常州千红生化制药股份有限公司 2025年员工持股 | | | | 计划(草案)》 | | 持有人 | 指 | 参加本员工持股计划的公司员工 | | 持有人会议 | 提 | 本员工持股计划持有人会议 | | 管理委员会 | 損 | 本员工持股计划管理委员会 | | 中国证监会 | 損 | 中国证券监督管理委员会 | | 深 ...

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology industry [1]. Core Views - The report highlights a positive change in the specialty raw materials sector, recommending companies such as Aorite and Prolo Pharmaceuticals [1]. - The report suggests that the Q3 performance of raw material pharmaceutical companies has reached a bottom, indicating potential recovery in profitability as high-cost inventory is consumed [19][20]. Summary by Sections Investment Highlights - The recommended sub-industry rankings are: Innovative Drugs > Research Services > CXO > Traditional Chinese Medicine > Medical Devices > Pharmacies [3][12]. - Specific stock recommendations include: - From raw materials: Aorite, Qianhong Pharmaceutical - From Traditional Chinese Medicine: Zorui Pharmaceutical, Fangsheng Pharmaceutical, Dong'e Ejiao - From medical devices: United Imaging Healthcare, Yuyue Medical - From AI pharmaceuticals: Jingtai Holdings - From GLP-1 sector: Lianbang Pharmaceutical, Borui Pharmaceutical, Zhongsheng Pharmaceutical, and Innovent Biologics - From PD-1/VEGF dual antibodies: Sanofi Biopharmaceuticals, Kangfang Biologics, and Rongchang Biopharmaceuticals - From innovative drugs: Innovent Biologics, BeiGene, HengRui Medicine, Zai Lab, Baillie Tianheng, Kelun Pharmaceutical, Dize Pharmaceutical, and Haizheng Pharmaceutical [3][15]. Industry Trends - The A-share pharmaceutical index has seen a year-to-date increase of 18.2%, while the Hang Seng Biotechnology Index has increased by 76.6% [6][11]. - The report notes that the raw material pharmaceutical sector is under pressure due to high base effects and declining prices, with significant revenue impacts [19][20]. R&D Progress and Company Dynamics - Recent approvals include Novartis' radioligand therapy drug, which received dual indications for prostate cancer treatment [2]. - The report provides an overview of ongoing clinical trials and drug approvals, emphasizing the importance of innovation in the pharmaceutical sector [30]. Market Performance - The report indicates that the pharmaceutical sector has experienced adjustments, with notable stock performances including significant gains for companies like Hezhong China (+61%) and Wanze Shares (+30%) [11]. - The report also highlights the performance of various pharmaceutical stocks, noting both gains and losses in the market [16][17]. Raw Material Pricing Trends - The price of 6-APA has dropped significantly, from 370 RMB/kg in 2022 to 180 RMB/kg in October 2025, a decrease of 51% [23]. - The price of Amoxicillin has also decreased from 320 RMB/kg in January 2023 to 190 RMB/kg in October 2025, a decline of 41% [23]. Conclusion - The report suggests that as high-cost inventory is depleted, the gross margins for raw material producers are expected to improve, indicating a potential recovery in profitability for companies like Fuxiang Pharmaceutical and Lukang Pharmaceutical [19][23].

Market Overview - The precision medicine sector experienced a decline of 1.77% on November 4, with TuoJing Life leading the drop [1][2] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] Stock Performance - Notable stock performances in the precision medicine sector included: - RenDu Bio (688193) closed at 52.90, up 1.05% with a trading volume of 7076.23 hands and a transaction value exceeding 36.99 million yuan [1] - TuoJing Life (300642) closed at 22.73, down 2.86% with a trading volume of 78,200 hands and a transaction value of 178 million yuan [2] - Other companies like DaAn Gene (002030) and Anke Bio (300009) showed minimal changes, with DaAn Gene remaining flat at 6.57 and Anke Bio down 0.55% to 10.84 [1][2] Capital Flow - The precision medicine sector saw a net outflow of 979 million yuan from institutional investors, while retail investors contributed a net inflow of 642 million yuan [2][3] - Specific stock capital flows indicated: - GuoMai Technology (002093) had a net inflow of 8.61 million yuan from institutional investors, while retail investors saw a net outflow of 15.98 million yuan [3] - TuoJing Life experienced minimal net inflow from institutional investors at 25,000 yuan, with retail investors also showing a slight outflow [3]